U.S. Food and Drug Administration Inspections of Clinical Investigators: Overview of Results from 1977 to 2009

Abstract

The U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research is responsible for evaluating drug safety and efficacy, including oversight of clinical trials and principal investigators. The FDA Clinical Investigator Inspection List (CIIL) contains online, detailed, relevant information of all FDA inspections. We reviewed FDA inspections of clinical investigators to ascertain their outcome and included all inspections on the list (July 1977 through December 31, 2009; n ¼ 9,481 inspections). Eighty-eight percent of inspections were "data audit" (primary purpose ¼ verification of data), and the rest (12%) were "for cause." The number of inspections each year significantly increased over time (P < 0.0001) and averaged 350 per year in the past decade. No deficiencies were found in only 11.2% of all "data audit" and 5% of all "for cause" inspections. Only 31% of inspections resulted in "no action indicated." About two thirds of inspections resulted in some finding, requiring either voluntary investigator action (61.3% of inspections) or official FDA action (3.9%). The most frequently cited deficiencies were failure to follow investigational plan (34%), inadequate informed consent form (28%), and inadequate/inaccurate records (27%). In conclusion, over the past decade, the FDA has performed approximately 350 inspections per year, with the number increasing over time. The vast majority of FDA inspections yield deficiency findings and, as a result, only about one third of inspections have an outcome of "no action indicated." Clin Cancer Res; 20(13); 3364-70. Ó2014 AACR.

Supervisión de ensayos clínicos en hospitales del Seguro Social de Salud del Perú: enfoque administrativo y regulatorio

“…Otros estudios no han reportado de forma específica las observaciones relacionadas a bioseguridad o calibración de equipos, pero estas podrían haber sido incluidas en otras categorías generales como «seguridad» o «aseguramiento de la calidad» (5,6) . El presente estudio encontró que hubo reducción en las observaciones relacionadas a bioseguridad, de 16% en el 2016 a ninguna en el 2017 y 2018, posiblemente por la supervisión constante que se realiza.…”

“…Existe escasa literatura sobre observaciones generadas durante la supervisión a EC y esta corresponde al reporte de patrocinadores y agencias reguladoras (5)(6)(7) . Sin embargo, en Motivación para realizar el estudio.…”

Antibiotic-resistantSalmonella speciesandEscherichia coliin broiler chickens from farms, abattoirs and open markets in selected districts of Zambia

“…and E. coli , identification, confirmation of the isolates and antibiotic susceptibility testing (AST). Laboratory protocols for bacterial isolation recommended by the Food and Drug Administration’s Bacteriological Analytical Manual were used with few modifications (14, 16). All media used were prepared according to manufacturer’s instructions.…”

Blockchain protocols in clinical trials: Transparency and traceability of consent

“…The FDA noted a global trend in the decrease in frequency of these issues in their investigations: in comparing 2000–2009 to 1990–1999, the frequency of issues related to the consent process in reviewed clinical trials were reduced by a factor 4 7 . However, the study by Seife 8 questioned the FDA results 9 .…”